The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy

We have demonstrated that microtubule destabilizing agents (MDAs) can sensitize tumors to oncolytic vesicular stomatitis virus (VSVΔ51) in various preclinical models of cancer. The clinically approved T-DM1 (Kadcyla®) is an antibody-drug conjugate consisting of HER2-targeting trastuzumab linked to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Arulanandam, Rozanne, Taha, Zaid, Garcia, Vanessa, Selman, Mohammed, Chen, Andrew, Varette, Oliver, Jirovec, Anna, Sutherland, Keara, Macdonald, Elizabeth, Tzelepis, Fanny, Birdi, Harsimrat, Alluqmani, Nouf, Landry, Anne, Bergeron, Anabel, Vanderhyden, Barbara, Diallo, Jean-Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244474/
https://www.ncbi.nlm.nih.gov/pubmed/32444806
http://dx.doi.org/10.1038/s42003-020-0972-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244474/
https://www.ncbi.nlm.nih.gov/pubmed/32444806
http://dx.doi.org/10.1038/s42003-020-0972-7

Ejemplares similares